Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00437242 · ClinicalTrials.gov registry record · Phase 1
Odiparcil QT Definitive Study
A Phase 1 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00437242 is a Phase 1 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 54 participants.
The verdict
NCT00437242, a Phase 1 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This study is being completed to demonstrate the lack of effect of repeat dosing with Odiparcil on the QTc interval.
Interventions
- DRUG Odiparcil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00437242
The ClinicalTrials.gov registry entry for NCT00437242 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Odiparcil is the first listed.
NCT00437242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00437242 about?
NCT00437242 is a clinical study titled "Odiparcil QT Definitive Study". This study is being completed to demonstrate the lack of effect of repeat dosing with Odiparcil on the QTc interval.
What is the current status of trial NCT00437242?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2006-10.
What interventions are being tested in trial NCT00437242?
The interventions under investigation include: Odiparcil (DRUG).
Who is sponsoring clinical trial NCT00437242?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.